{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:55:12Z","timestamp":1790517312382,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.beha.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T08:17:55Z","timestamp":1478247475000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Treatment of splenic marginal zone lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Christina","family":"Kalpadakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerassimos A.","family":"Pangalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1596-3630","authenticated-orcid":false,"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.07.004_bib1","series-title":"World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues","first-page":"185","article-title":"Splenic B-cell marginal zone lymphoma","author":"Isaacson","year":"2008"},{"key":"10.1016\/j.beha.2016.07.004_bib2","first-page":"148","article-title":"Splenic lymphoma with circulating villous lymphocytes\/splenic marginal-zone lymphoma","volume":"36","author":"Catovsky","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2016.07.004_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib5","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chacon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d\u2019Hematologie Cellulaire (GFHC)","volume":"93","author":"Troussard","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2141.2003.04165.x","article-title":"Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients","volume":"120","author":"Parry-Jones","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib8","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.20596","article-title":"Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients","volume":"101","author":"Iannitto","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.004_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.11893","article-title":"Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles","volume":"100","author":"Arcaini","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.004_bib10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2002-10-3230","article-title":"Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case\u2013control study","volume":"102","author":"Mele","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib11","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1038\/sj.leu.2400878","article-title":"Chronic malaria and splenic lymphoma: clues to understanding lymphoma evolution","volume":"11","author":"Bates","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib12","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V85.6.1603.bloodjournal8561603","article-title":"Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes","volume":"85","author":"Zhu","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0046-8177(99)90010-2","article-title":"Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes","volume":"30","author":"Miranda","year":"1999","journal-title":"Hum Pathol"},{"key":"10.1016\/j.beha.2016.07.004_bib14","first-page":"470","article-title":"Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection","volume":"90","author":"Traverse-Glehen","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.004_bib15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V99.4.1299","article-title":"Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course","volume":"99","author":"Algara","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2119\/2005-00001.Stamatopoulos","article-title":"Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma","volume":"10","author":"Stamatopoulos","year":"2004","journal-title":"Mol Med"},{"key":"10.1016\/j.beha.2016.07.004_bib17","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2002-01-0169","article-title":"V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in\u00a0vivo","volume":"100","author":"Zhu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib18","first-page":"1811","article-title":"Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome","volume":"29","author":"Kalpadakis","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.beha.2016.07.004_bib19","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications","volume":"26","author":"Bikos","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2141.1998.00764.x","article-title":"Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Francais d\u2019Hematologie Cellulaire (GFHC) study","volume":"101","author":"Troussard","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib21","first-page":"71","article-title":"Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q","volume":"86","author":"Sole","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.004_bib22","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/sj.leu.2403909","article-title":"Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases","volume":"19","author":"Callet-Bauchu","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.07.004_bib25","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.07.004_bib26","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and multiple other NF-\u03baB pathway genes in splenic marginal zone lymphoma","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.004_bib28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib29","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2016.07.004_bib30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Mart\u00ednez","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0609.2005.00578.x","article-title":"Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma","volume":"76","author":"Iannitto","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.004_bib33","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/annonc\/mdt507","article-title":"Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma","volume":"25","author":"Meyer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2008.07301.x","article-title":"High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis","volume":"143","author":"Dungarwalla","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib36","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2004-10-3898","article-title":"Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis","volume":"106","author":"Ruiz Ballesteros","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib37","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Splenic Marginal Zone Lymphoma Study Group risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Splenic Marginal Zone Lymphoma Study Group (SMZLSG). Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","author":"Montalban","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib40","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3109\/10428194.2014.897703","article-title":"Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group","volume":"55","author":"Kalpadakis","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/PAS.0b013e318271243d","article-title":"Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?","volume":"36","author":"Ponzoni","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.beha.2016.07.004_bib43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","article-title":"Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases","volume":"78","author":"Mulligan","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib44","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"8","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib46","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3109\/10428194.2015.1092529","article-title":"Perioperative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma","volume":"57","author":"Pata","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO;2-W","article-title":"Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes","volume":"91","author":"Franco","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.004_bib48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.004_bib49","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma:from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib50","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.004_bib51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib52","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2016.07.004_bib53","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2013.845884","article-title":"Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?","volume":"55","author":"Kalpadakis","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.12036","article-title":"Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma","volume":"159","author":"Else","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2016.07.004_bib55","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.3109\/10428194.2016.1157877","article-title":"No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab","volume":"57","author":"Kalpadakis","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib56","series-title":"Validation of the simplified prognostic score for SMZL of the SMZLSG (SMZL study group) in a series of patients treated with rituximab monotherapy, and long term outcome of rituximab responders EHA Congress","author":"Kalpadakis","year":"2015"},{"key":"10.1016\/j.beha.2016.07.004_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2141.1997.3523168.x","article-title":"Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes","volume":"99","author":"Bolam","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1034\/j.1600-0609.2002.02759.x","article-title":"Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes","volume":"69","author":"Yasukawa","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.leu.2401710","article-title":"Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes","volume":"14","author":"Lefrere","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hon.717","article-title":"Low dose 2-CdA schedule activity in splenic marginal zone lymphomas","volume":"21","author":"Riccioni","year":"2003","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2005.00426.x","article-title":"Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes","volume":"75","author":"Iannitto","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428190009054887","article-title":"Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes","volume":"40","author":"Lefrere","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib63","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/sj.leu.2403440","article-title":"Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update","volume":"18","author":"Lefr\u00e8re","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib64","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/annonc\/mdt181","article-title":"Significant efficacy of 2-chlorodeoxyadenosine\u00b1rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up","volume":"24","author":"Cervetti","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.leukres.2009.04.003","article-title":"2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma","volume":"34","author":"Orciuolo","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2016.07.004_bib66","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.3109\/10428194.2015.1029925","article-title":"Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study","volume":"56","author":"Iannitto","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.004_bib67","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2016.07.004_bib68","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib69","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CLML.2010.n.079","article-title":"Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma","volume":"10","author":"Cheson","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2016.07.004_bib70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.07.004_bib72","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.004_bib73","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib74","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3816\/CLM.2006.n.033","article-title":"Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia","volume":"6","author":"Fabbri","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.beha.2016.07.004_bib75","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2016.07.004_bib76","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.beha.2016.07.004_bib77","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.beha.2016.07.004_bib78","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib79","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1708.1708","article-title":"Mature follow-up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma","volume":"124","author":"Gopal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.004_bib80","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib81","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib82","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2016.07.004_bib83","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.3324\/haematol.2015.139329","article-title":"Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi","volume":"101","author":"Sacchi","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.004_bib84","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib85","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A\u00a0phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.004_bib86","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","author":"Conconi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.004_bib87","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","author":"Di Bella","year":"2010","journal-title":"Blood"},{"issue":"117","key":"10.1016\/j.beha.2016.07.004_bib88","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"1","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.004_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.004_bib90","series-title":"Risk of histologic transformation (HT) in splenic marginal zone lymphomas (SMZL) patients with rituximab EHA Congress","author":"Kalpadakis","year":"2016"},{"key":"10.1016\/j.beha.2016.07.004_bib91","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00000478-200110000-00007","article-title":"Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases","volume":"25","author":"Camacho","year":"2001","journal-title":"Am J Surg Pathol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:52:31Z","timestamp":1601178751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":91,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1521692616300846"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.07.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of splenic marginal zone lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}